Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Study reveals insights into how FMDV interacts with immune system
The study revealed that the interaction between FMDV and the immune system helps the virus to persist in animals such as African buffalo.

Findings could provide clues about how to increase vaccine protection longevity.

Researchers at The Pirbright Institute have revealed how the foot-and-mouth-disease virus (FMDV) interacts with lymphoid tissues to create vaccines that give long-lasting immunity to livestock.

The study found that the interaction between FMDV and the immune system helps the virus to persist in animals such as African buffalo, enabling them to become carriers of the disease and, therefore, pose a risk to other susceptible livestock.

Given that current vaccinations only give short-term protection, scientists believe that better knowledge of immunity to FMDV might lead to the development of longer-lasting vaccines that would benefit those farmers whose livelihoods depend on them.

In the study, scientists used a mouse model to investigate how FMDV persists in African buffalo and discovered that FMDV binds to cells in the immune system called follicular dendritic cells.
Follicular dendritic cells are found in lymphoid tissues, part of the adaptive immune response, and allow the immune system to mount a specific response.

The study also found that FMDV binds to a receptor known as CR2/CR1, which is essential for trapping and retaining the virus that, in turn, leads to a better and longer-lived immune response. 

Researchers also revealed which lymphoid tissues were important in FMDV infection and correlated to researchers’ predictions on the origins of persistence in African buffalo. 

Professor Bryan Charleston, director of The Pirbright Institute and head of the Viral Immunology Group, said: “This research helps to bridge the knowledge gap of how the immune system deals with FMDV infection in large animals. Our extensive work in African buffalo, a natural host of the disease, allowed us to predict why and how persistence may occur and then test this theory in a small animal model. 

"This has given us new insights into the immune responses to FMDV and could provide clues about how to increase vaccine protection longevity.” 

 

Become a member or log in to add this story to your CPD history

Animal Medicines Amnesty returns this November

News Story 1
 Veterinary practices are being urged to help owners safely dispose of any unused and expired pet medicines - not just antibiotics - during November's Animal Medicines Amnesty.

Organised by the Responsible Use of Medicines Alliance Companion Animal and Equine (RUMA CA&E), the initative is supported by a range of cross-sector organisations.

Practices are encouraged to use the campaign to engage the whole practice team and raise awareness of the safe disposal of medicines with clients. Learn how your practice can get involved at rumacae.org.uk 

Click here for more...
News Shorts
Bluetongue RZ extended across Scotland

The Scottish Government has announced an extension to a Bluetongue Restricted Zone that is in place in south-west Scotland.

From 3 October, the Restricted Zone will be extended to cover the whole of Scotland. The Animal, Plant and Health Agency (APHA) says this is in response to further disease spread, as well as simplify trading conditions ahead of the autumn.

Since the whole country will share a disease status, it will no longer be necessary to have a movement license to move susceptible livestock around the country. Restrictions on germinal products remain.

As of 1 October 2026, there were 1,979 cases of BTV-3 in England, 389 cases in Wales and 40 cases in Scotland.